- Home
- ARQT vs IRS Comparison
ARQT vs IRS Comparison
Compare ARQT & IRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- IRS
- Stock Information
- Founded
- ARQT 2016
- IRS 1943
- Country
- ARQT United States
- IRS Argentina
- Employees
- ARQT N/A
- IRS N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- IRS Homebuilding
- Sector
- ARQT Health Care
- IRS Real Estate
- Exchange
- ARQT Nasdaq
- IRS Nasdaq
- Market Cap
- ARQT 1.1B
- IRS 1.1B
- IPO Year
- ARQT 2020
- IRS 1994
- Fundamental
- Price
- ARQT $14.99
- IRS $15.33
- Analyst Decision
- ARQT Strong Buy
- IRS Strong Buy
- Analyst Count
- ARQT 4
- IRS 1
- Target Price
- ARQT $15.50
- IRS $12.62
- AVG Volume (30 Days)
- ARQT 2.2M
- IRS 254.6K
- Earning Date
- ARQT 11-06-2024
- IRS 02-03-2025
- Dividend Yield
- ARQT N/A
- IRS 10.63%
- EPS Growth
- ARQT N/A
- IRS N/A
- EPS
- ARQT N/A
- IRS N/A
- Revenue
- ARQT $138,708,000.00
- IRS $370,002,935.00
- Revenue This Year
- ARQT $208.32
- IRS N/A
- Revenue Next Year
- ARQT $48.56
- IRS N/A
- P/E Ratio
- ARQT N/A
- IRS N/A
- Revenue Growth
- ARQT 182.84
- IRS N/A
- 52 Week Low
- ARQT $2.60
- IRS $7.32
- 52 Week High
- ARQT $15.77
- IRS $17.67
- Technical
- Relative Strength Index (RSI)
- ARQT 67.53
- IRS 45.22
- Support Level
- ARQT $12.66
- IRS $16.14
- Resistance Level
- ARQT $15.02
- IRS $17.23
- Average True Range (ATR)
- ARQT 1.11
- IRS 0.87
- MACD
- ARQT 0.14
- IRS -0.35
- Stochastic Oscillator
- ARQT 78.92
- IRS 16.13
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.